LEXINGTON, Mass., May 22, 2025 /PRNewswire/ -- Accent Therapeutics, a clinical-stage biopharmaceutical company pioneering novel, targeted, small molecule cancer therapeutics, today announced that a ...

The MarketWatch News Department was not involved in the creation of this content. -- Poster presentation to highlight the ongoing global Phase 3 ASP-1929-381 study at ASCO 2025 -- Global patient ...

Circle Pharma to Present Trials in Progress Poster on CID-078, a First-in-Class Cyclin A/B Inhibitor, at the ASCO 2025 Annual Meeting Circle Pharma, a clinical-stage biopharmaceutical company ...

First five patients in Part C (expansion) of THIO-101 Phase 2 clinical trial enrolled in Taiwan and Turkey CHICAGO, Oct. 27, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) ...

CAMBRIDGE, Mass., April 23, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase ...

SAN FRANCISCO, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, ...

“CID-078 exemplifies Circle Pharma’s commitment to advancing new treatments for patients with cancer,” said Michael C. Cox, PharmD, MHSc, BCOP, SVP, and head of early development of Circle Pharma.

SAN DIEGO, May 22, 2025 /PRNewswire/ -- Rakuten Medical, Inc., a global biotechnology company developing and commercializing Alluminox™ platform-based photoimmunotherapy, today announced that it will ...